Uremic Toxins Inhibit the Platelet Malonyldialdehyde Production Rate
Platelet cyclo-oxygenase activity is known to be low in uremic patients1,2, but it is still lower in maintenance hemodialysis patients3. Malonyldialdehyde (MDA) is one of the terminal substances from arachidonic acid, which is converted to prostaglandins by cyclo-oxygenase. Although some MDA are produced through other pathways, the platelet MDA production rate is used to evaluate platelet cyclo-oxygenase activity and is a guideline in detecting the abnormality of prostaglandin metabolism. The aim of this study is to find out the inhibiting factor of this platelet MDA production rate in hemodialysis patients. We observed the level of inhibition of the activity of normal platelets incubated with several kinds of substances which are suspected to be uremic toxins.
KeywordsHemodialysis Patient Platelet Rich Plasma Normal Platelet Uremic Toxin Inhibition Index
Unable to display preview. Download preview PDF.
- 2.O. Ylikorkala, K. Huttunen, J. Jarvi, and L. Viinikka, Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis, Clin. Nephrol. 18:83 (1981).Google Scholar
- 3.H. Tanaka, K. Umimoto, N. Izumi, K. Nishimoto, T. Maekawa, T. Kishimoto, and M. Maekawa, Platelet life span in uraemia, Proc. Euro. Dial. Transpl. Assoc. 21:306 (1984).Google Scholar
- 6.G. Remuzzi, D. Marchesi, M. Livio, A. Schieppati, G. Mecca, M. B. Donati, and G. De Gaetano, Prostaglandins, plasma factors, and hemostasis in uremia, in: "Hemostasis, Prostaglandins, and Renal Disease," G. Remuzzi, G. Mecca, G. De Gaetano, eds., Raven Press, New York (1980).Google Scholar